Considering the roles of oxidative stress and neuroinflammation in HD, targeting PKM2 and modulating the IL-6/JAK2/STAT3 pathway with a multifaceted therapeutic may offer a novel strategy to mitigate disease progression. The gene discussed is PKM; the disease is Huntington disease.